Rajesh K. Gupta, Ph.D. Biologics Quality & Regulatory Consultants, LLC, North Potomac
Coronavirus disease (COVID-19) is a terrifying illness with high morbidity and mortality throughout the world and with devastating effects on businesses, economies, livelihood of individuals and producing depression/fear among populations due to prolonged lock downs. The only way to control the disease appears to be by developing herd immunity, either by infection or by universal vaccination. Achieving herd immunity by infection seems horrific with a significant burden on healthcare systems and sacrificing vulnerable population, including older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer. Achieving herd immunity through vaccination will take at least several months to years after development of a safe and effective vaccine. Typically, it takes a decade or more to develop a vaccine. Scientists and vaccinologists from academia, industry and Government organizations are enthusiastically working on more than 100 vaccine candidates to develop a safe and effective vaccine. There are numerous scientific, technical, manufacturing, and regulatory challenges and risks in developing vaccines in general, particularly under a fast timeline. This Webinar will go over the challenges and risks in developing Coronavirus vaccines with a view to identifying these for resolution and mitigation along with development of the vaccines.
Presented by Rajesh K. Gupta, Ph.D. Biologics Quality & Regulatory Consultants, LLC, North Potomac, USA
ROLE OF SERUM INSTITUTE OF INDIA LIMITED IN DEVELOPMENT AND MANUFACTURE OF COVID 19 VACCINE
Presented by Harish Rao, General Manager at Serum Institute of India Ltd and Amar Shrivastava, Senior Manager at Serum Institute of India Ltd